Global markets have been experiencing significant volatility due to escalating trade tensions, particularly between the U.S. and China, which has affected investor sentiment and led to fluctuations in major indices. For investors interested in exploring opportunities beyond the mainstream market, penny stocks—though an older term—remain a relevant area of investment that can offer both affordability and growth potential. These stocks typically represent smaller or newer companies, and when backed by strong financials, they may present valuable prospects for those willing to explore less conventional options.
Top 10 Penny Stocks Globally
| Name | Share Price | Market Cap | Rewards & Risks |
| CNMC Goldmine Holdings (Catalist:5TP) | SGD0.425 | SGD172.25M | ✅ 4 ⚠️ 2 View Analysis > |
| Yangzijiang Shipbuilding (Holdings) (SGX:BS6) | SGD2.04 | SGD8.04B | ✅ 5 ⚠️ 0 View Analysis > |
| Angler Gaming (NGM:ANGL) | SEK3.60 | SEK269.95M | ✅ 4 ⚠️ 3 View Analysis > |
| SKP Resources Bhd (KLSE:SKPRES) | MYR0.80 | MYR1.25B | ✅ 5 ⚠️ 2 View Analysis > |
| NEXG Berhad (KLSE:NEXG) | MYR0.26 | MYR723.36M | ✅ 4 ⚠️ 2 View Analysis > |
| DXN Holdings Bhd (KLSE:DXN) | MYR0.50 | MYR2.49B | ✅ 5 ⚠️ 0 View Analysis > |
| Sarawak Plantation Berhad (KLSE:SWKPLNT) | MYR2.26 | MYR630.61M | ✅ 5 ⚠️ 2 View Analysis > |
| Lever Style (SEHK:1346) | HK$1.03 | HK$643.57M | ✅ 4 ⚠️ 2 View Analysis > |
| Warpaint London (AIM:W7L) | £3.60 | £290.83M | ✅ 5 ⚠️ 3 View Analysis > |
| Foresight Group Holdings (LSE:FSG) | £3.41 | £386.35M | ✅ 4 ⚠️ 1 View Analysis > |
Click here to see the full list of 5,651 stocks from our Global Penny Stocks screener.
We're going to check out a few of the best picks from our screener tool.
Jacobio Pharmaceuticals Group (SEHK:1167)
Simply Wall St Financial Health Rating: ★★★★☆☆
Overview: Jacobio Pharmaceuticals Group Co., Ltd. is an investment holding company focused on the in-house discovery and development of oncology therapies, with a market cap of HK$2.66 billion.
Operations: The company's revenue segment is derived from the research and development of new drugs, amounting to CN¥155.71 million.
Market Cap: HK$2.66B
Jacobio Pharmaceuticals Group, with a market cap of HK$2.66 billion, is focused on oncology therapies but remains pre-revenue. Despite being unprofitable, the company has managed to reduce its losses by 29.6% annually over the past five years and maintains more cash than total debt. Its short-term assets significantly exceed both short- and long-term liabilities, suggesting a solid financial position for covering obligations. The management team and board are experienced, with average tenures of 5.2 and 4.7 years respectively. Recent changes in its Nomination Committee reflect active governance adjustments amidst ongoing business developments.
- Navigate through the intricacies of Jacobio Pharmaceuticals Group with our comprehensive balance sheet health report here.
- Assess Jacobio Pharmaceuticals Group's future earnings estimates with our detailed growth reports.
Sheng Siong Group (SGX:OV8)
Simply Wall St Financial Health Rating: ★★★★★★
Overview: Sheng Siong Group Ltd is an investment holding company that operates a chain of supermarket retail stores in Singapore, with a market cap of SGD2.50 billion.
Operations: The company generates revenue from its supermarket operations by selling consumer goods, amounting to SGD1.43 billion.
Market Cap: SGD2.5B
Sheng Siong Group, with a market cap of SGD2.50 billion, demonstrates financial stability and growth potential within the supermarket retail sector. The company is debt-free, which alleviates concerns over interest coverage and cash flow constraints. Its Return on Equity stands at 25.5%, indicating efficient profit generation from shareholders' equity. Despite a slight decline in net profit margins to 9.6% from 9.8% last year, earnings have grown by 5.5% annually over five years, with forecasts suggesting continued growth at 4.27%. Recent announcements include a final dividend of SGD0.032 per share for FY2024 pending shareholder approval.
- Click here to discover the nuances of Sheng Siong Group with our detailed analytical financial health report.
- Examine Sheng Siong Group's earnings growth report to understand how analysts expect it to perform.
Liaoning SG Automotive Group (SHSE:600303)
Simply Wall St Financial Health Rating: ★★★★☆☆
Overview: Liaoning SG Automotive Group Co., Ltd. manufactures and sells automobiles, axles, and other auto parts in China, with a market cap of CN¥2.52 billion.
Operations: Liaoning SG Automotive Group Co., Ltd. has not reported any revenue segments.
Market Cap: CN¥2.52B
Liaoning SG Automotive Group, with a market cap of CN¥2.52 billion, faces financial challenges as its short-term assets (CN¥1.2 billion) do not cover short-term liabilities (CN¥1.5 billion). The company is currently unprofitable, with losses increasing at a significant rate over the past five years. Its debt to equity ratio has risen from 29% to 45.8%, though the net debt to equity ratio remains satisfactory at 35.7%. While it has sufficient cash runway for more than three years based on current free cash flow, management and board experience are limited, potentially impacting strategic direction.
- Unlock comprehensive insights into our analysis of Liaoning SG Automotive Group stock in this financial health report.
- Review our historical performance report to gain insights into Liaoning SG Automotive Group's track record.
Taking Advantage
- Explore the 5,651 names from our Global Penny Stocks screener here.
- Ready To Venture Into Other Investment Styles? We've found 25 US stocks that are forecast to pay a dividend yeild of over 6% next year. See the full list for free.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Valuation is complex, but we're here to simplify it.
Discover if Sheng Siong Group might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com